Figure 4 | Modern Pathology

Figure 4

From: β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation

Figure 4

β-Catenin expression in invasive breast carcinomas according to the molecular subtypes. One representative case of each subtype is shown: a luminal (ie, oestrogen receptor-positive (a) and HER2-negative (b)) carcinoma displaying β-catenin membranous expression without nuclear expression (c); a HER2 (ie, oestrogen receptor-negative (d) and HER2-positive (e)) carcinoma displaying β-catenin membranous expression without nuclear expression (f); and a basal-like (ie, oestrogen receptor-negative (g) and HER2-negative (h)) carcinoma showing strong β-catenin nuclear accumulation and lack of β-catenin membranous expression (i).

Back to article page